Roche Gives Up on India Patent for Breast Cancer Drug
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin in India, the Swiss company said on Friday, as Western drugmakers come under pressure over high prices in the fast-growing market. The Kolkata Patent Office said earlier this month that it had dismissed certain patent applications filed by Roche, because the company had failed to submit the applications for Herceptin correctly. "Roche has come to the conclusion not to pursue Indian Patent No. 205534 (the secondary patent) and the related divisional applications," a Roche spokesman said in an emailed statement.
Help employers find you! Check out all the jobs and post your resume.
Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin in India, the Swiss company said on Friday, as Western drugmakers come under pressure over high prices in the fast-growing market. The Kolkata Patent Office said earlier this month that it had dismissed certain patent applications filed by Roche, because the company had failed to submit the applications for Herceptin correctly. "Roche has come to the conclusion not to pursue Indian Patent No. 205534 (the secondary patent) and the related divisional applications," a Roche spokesman said in an emailed statement.
Help employers find you! Check out all the jobs and post your resume.